Case Reports in Nephrology · Published 2025-01-01 · DOI 10.1155/crin/6626611
Conclusion: In a patient with longstanding conditions and multiple comorbidities, difelikefalin showed sustained effectiveness against H1-receptor antagonist– and gabapentin–resistant CKD-aP. Difelikefalin was well tolerated over the long term.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →